Viewing Study NCT05550558


Ignite Creation Date: 2025-12-25 @ 12:02 AM
Ignite Modification Date: 2025-12-25 @ 10:00 PM
Study NCT ID: NCT05550558
Status: NOT_YET_RECRUITING
Last Update Posted: 2022-09-28
First Post: 2022-09-20
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module